Introduction
============

*Streptomycetes* are well known as prolific producers of bioactive secondary metabolites including more than half of antibiotics as well as antitumor agents, antifungal compounds and vitamins, which have remarkable pharmacological, and industrial importance. Biosynthetic genes for antibiotics and other secondary metabolites are typically clustered together on the chromosomes ([@B7]; [@B30]) or the plasmids ([@B35]), designated as BGC, and are subject to multi-level and complex regulation cascades. Among them, CSRs provide direct contributions to the biosynthesis of antibiotics by responding to pleiotropic regulators ([@B34]), global regulators ([@B44]; [@B16]; [@B21]), and different kinds of regulatory small molecules ([@B46]; [@B54]), subsequently regulating expression of the other biosynthetic genes within their cognate clusters. However, not all the BGCs share a same regulatory scheme. Some of them, such as jadomycin BGC, harbor multiple CSRs ([@B55]), some of them, such as sansanmycin BGC, contain a single CSR ([@B28]), while the others, such as lincomycin BGC, lack any distinct CSRs ([@B18]). Generally, CSRs belong to a variety of regulatory protein families, which are divided by sequence or structural similarities, including SARP (*Streptomyces* antibiotic regulatory protein) family, LAL (large ATP-binding regulators of the LuxR) family, TetR family, and so on.

The most common and best studied CSRs are those of the SARP family in *Streptomyces*, including ActII-ORF4 within actinorhodine BGC as well as RedD within undecylprodigiosin BGC in *Streptomyces coelicolor* ([@B42]; [@B2]), DnrI within daunorubicin BGC in *Streptomyces peucetius* ([@B39]), and CcaR within cephamycin-clavulanic acid BGC in *Streptomyces clavuligerus* ([@B37]). These members are classified by having an N-terminal HTH DBD subject to OmpR-type and a transcriptional activation domain ([@B47]), which generally positively regulate the biosynthesis of secondary metabolites ([@B39]; [@B43]). The target promoters of these members usually contain direct repeats, for instance, direct heptameric repeats (5'-TCGAGXX-3') with 4 bp spacers are conserved upstream the -10 regions of the promoters targeted by ActII-ORF4 and DnrI ([@B43]). The LAL family members usually function as activators in *Streptomyces* too, and comprise an N-terminal ATP-binding domain with a C-terminal LuxR-type DBD, including PikD within pikromycin BGC in *Streptomyces venezuelae* ([@B48]), RapH within rapamycin BGC in *Streptomyces hygroscopicus* ([@B26]), and AveR within avermectin BGC in *Streptomyces avermitilis* ([@B12]). Compared to the SARP and LAL families, TetR family members are widely distributed in various bacteria, including ActR within actinorhodin BGC in *S. coelicolor* ([@B41]), TetR in *Escherichia coli* ([@B25]), RolR in *Corynebacterium glutamicum* ([@B29]), LplR in *Rhodococcus erythropolis* ([@B40]), and VtpR in *Vibrio tubiashii* ([@B13]). The TetR family members usually function as transcriptional repressors and consist of an N-terminal DBD and a C-terminal functional domain, which can bind to one or more ligands, subsequently losing the DNA-binding activity and turning on transcription of the target genes ([@B53]; [@B8]).

Previously, we have reported that LmbU functions as an activator belonging to a novel regulatory family, LmbU family ([@B18]; [@B45]), and promotes lincomycin biosynthesis by directly regulating transcription of the biosynthetic genes ([@B18]). The conserved binding site of LmbU is a palindromic sequence 5'-CGCCGGCG-3', which was found in the promoter regions of the *lmbA* and *lmbW* genes. While, the regulatory mechanism of LmbU to other genes lack of the conserved motif is still unknown. In addition, because LmbU and its homologs have no significant sequence and structural similarities to other known CSRs, the binding pattern and functional domains of LmbU are also unclear. In the present study, we characterized the DBD (HTH motif) of LmbU and demonstrated that N-terminal of LmbU contains an AID, which was found in LmbU homologs within the BGCs of antibiotics, but not in that outside BGC of antibiotics. LmbU inhibits transcription of its own gene *in vivo*, and LmbU variant without AID can bind to *lmbUp* promoter. In addition, we revealed that LmbU can form homodimer by a disulfide bond *in vitro*.

Materials and Methods {#s1}
=====================

Homology Modeling, Sequence Alignment, and Phylogenetic Tree Analysis
---------------------------------------------------------------------

Secondary structure analysis of LmbU was performed by using an online software PredictProtein^[1](#fn01){ref-type="fn"}^. Homology modeling of LmbU was performed by using an online software SwissModel^[2](#fn02){ref-type="fn"}^. The templates used for LmbU modeling were chosen by ranking, including *Tt*Spo0J derived from *Thermus thermophiles* (GenBank Accession No. WP_011173975.1), *Hp*Spo0J derived from *Helicobacter pylori* (GenBank Accession No. ACJ08256.1), AtaR derived from *E. coli* (GenBank accession no. 6AJN_F), ParG derived from a multidrug resistance plasmid TP228 from *E. coli* (GenBank Accession No. ACV89876.1), AmrZ derived from *Pseudomonas aeruginosa* (GenBank Accession No. APJ53923.1), ω repressor derived from a plasmid Psm19035 from *Streptococcus pyogenes* (GenBank accession no. AAR27202.1), and Arc repressor derived from *Salmonella* bacteriophage P22 (GenBank Accession No. AAM81381.1). Sequence alignment of LmbU with its homologs and the targets of LmbU were carried out by using DNAMAN ([@B18]). Phylogenetic tree analysis was inferred by using MEGA v7.0.14 with the maximum likelihood method, the LmbU homologs were chosen by ranking ([@B5]; [@B19]).

Bacterial Strains, Plasmids, and Growth Conditions
--------------------------------------------------

The bacterial strains and plasmids used in this study are listed in [Table 1](#T1){ref-type="table"}. *E. coli* JM83, BL21 (DE3) and ET12567/pUZ8002 strains were used for plasmids construction, protein overexpression and *E. coli*-*Streptomyces* conjugation, respectively. *Streptomyces lincolnensis* wild-type strain NRRL 2936 and *lmbU* disruption strain JLUa2 were used for *xylTE* reporter assays *in vivo* ([@B32]; [@B19]). The pET-28a (+) plasmid was used for overexpression of LmbU and its variants, and the pIB139 plasmid was used for *xylTE* reporter analysis. *E. coli* strains were grown in liquid or on solid Luria-Bertani media at 37°C. *S. lincolnensis* NRRL 2936 and mutants were grown in liquid YEME medium or on solid SMA and ISP4 media at 28°C as described previously ([@B18]). The media were added with 50 μg/ml kanamycin, 50 μg/ml apramycin, and 30 μg/ml chloramphenicol as appropriate.

###### 

Strains and plasmids used in this study.

  Strain or plasmid       Genotype and/or description                                                                   Source or reference
  ----------------------- --------------------------------------------------------------------------------------------- ---------------------
  **Strains**                                                                                                           
  ***S. lincolnensis***                                                                                                 
  NRRL 2936               Wild-type, lincomycin producer                                                                NRRL, United States
  JLUa2                   NRRL 2936 Δ*lmbU*                                                                             [@B18]
  LNA                     NRRL 2936 attBΦC31::pATE152                                                                   [@B19]
  LUA                     JLUa2 attBΦC31::pATE152                                                                       [@B19]
  JAU01                   JLUa2 attBΦC31::pAU01                                                                         This study
  JAU02                   JLUa2 attBΦC31::pAU02                                                                         This study
  JAU03                   JLUa2 attBΦC31::pAU03                                                                         This study
  JAU06                   JLUa2 attBΦC31::pAU06                                                                         This study
  JAU07                   JLUa2 attBΦC31::pAU07                                                                         This study
  LNU                     NRRL 2936 attBΦC31::pUTE152                                                                   This study
  LUU                     JLUa2 attBΦC31::pUTE152                                                                       This study
  ***E. coli***                                                                                                         
  JM83                    F', ara, Δ(*lac-pro* AB), *rpsL*, (Str^r^), Φ80, *lacZ*ΔM15                                   [@B18]
  BL21 (DE3)              F^−^ *ompT hsdS gal dcm*                                                                      Novagen
  ET12567/pUZ8002         *dam-13*::Tn9 *dcm-6 hsdM*; containing the non-transmissible RP4 derivative plasmid pUZ8002   [@B20]
  **Plasmids**                                                                                                          
  pET-28a (+)             *E. coli* expression vector                                                                   Novagen
  pLU-02                  LmbU~1--161~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                    This study
  pLU-03                  LmbU~86--225~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                   This study
  pLU-04                  LmbU~1--142~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                    This study
  pLU-05                  LmbU~1--131~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                    This study
  pLU-06                  LmbU~58--225~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                   This study
  pLU-07                  LmbU~58--161~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                   This study
  pLU-13                  LmbU~113--225~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                  This study
  pLU-14                  LmbU~C12G~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                      This study
  pLU-15                  LmbU~C63G~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                      This study
  pLU-16                  LmbU~R101A~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                     This study
  pLU-17                  LmbU~R102A~ cloned in *Nde*I/*Eco*RI sites of pET-28a (+)                                     This study
  pSET152                 Integrative vector based on ΦC31 integrase                                                    [@B4]
  pATE152                 pSET152 carrying *xylTE* reporter gene controlled by *lmbAp* promoter                         [@B19]
  pEU139                  pIB139 with *lmbU* inserted downstream of *ermE^∗^p*                                          [@B18]
  pAU01                   pATE152 inserted with LmbU expression cassette                                                This study
  pAU02                   pATE152 inserted with LmbU~1--161~ expression cassette                                        This study
  pAU03                   pATE152 inserted with LmbU~86--225~ expression cassette                                       This study
  pAU06                   pATE152 inserted with LmbU~58--225~ expression cassette                                       This study
  pAU07                   pATE152 inserted with LmbU~58--161~ expression cassette                                       This study
  pUTE152                 pSET152 carrying *xylTE* reporter gene controlled by *lmbUp* promoter                         This study

Construction, Overexpression, and Purification of LmbU and Its Variants in *E. coli*
------------------------------------------------------------------------------------

To construct LmbU truncated variants, DNA fragments covering different regions of *lmbU* gene were amplified by PCR using primer pairs U02-F28a/R28, U03-F28a/R28, U04-F28a/R28, U05-F28a/R28, U06-F28a/R28, U07-F28a/R28, and U13-F28a/R28 listed in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. The amplified DNA fragments were inserted into the *Nde*I/*Eco*RI restriction sites of the pET-28a (+) vector, resulting in various expression plasmids pLU-02, pLU-03, pLU-04, pLU-05, pLU-06, pLU-07, and pLU-13, which were used for expression of LmbU~1--161~, LmbU~86--225~, LmbU~1--142~, LmbU~1--131~, LmbU~58--225~, LmbU~58--161~, and LmbU~113--225~.

To construct LmbU point-mutant variants, DNA fragments covering different upstream or downstream within *lmbU* genes were, respectively amplified by PCR using the primer pairs listed in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. Among them, primer pairs U-P1/U-RR-P2 with U-RR-P3/U-P4 were used for combined mutation of R101 and R102, primer pairs U-P1/U-R101-P2 with U-R101-P3/U-P4 were used for mutation of R101, primer pairs U-P1/U-R102-P2 with U-R102-P3/U-P4 were used for mutation of R102, primer pairs U-P1/U-C63-P2 with U-C63-P3/U-P4 were used for mutation of C63. The mutations were introduced by primers P2 and P3, R was replaced with A, and C was replaced with G. The corresponding DNA fragments of upstream and downstream of *lmbU* were inserted into the *Nde*I/*Eco*RI restriction sites of the pET-28a (+) vector by using Super Efficiency Fast Seamless Cloning kits (DoGene, China), resulting in various expression plasmids pLU-08, pLU-16, pLU-17, and pLU-15, which were used for expression of LmbU~RR~, LmbU~R101A~, LmbU~R102A~, and LmbU~C63G~. In addition, to construct LmbU point-mutant variant LmbU~C63G~, a DNA fragment was amplified by PCR using primer pairs U-C12-P1/U-R28a, and inserted into the *Nde*I/*Eco*RI restriction sites of the pET-28a (+) vector, resulting in expression plasmids pLU-14.

The obtained plasmids were transformed into *E. coli* BL21 (DE3) for protein expression as described previously ([@B18]). Briefly, The strains were cultivated at 37°C until OD~600~ reached about 0.6, isopropyl--D-1-thiogalactopyranoside (IPTG) was added and the cultures were then incubated at 16°C overnight. The proteins were released by sonication on ice and were purified using nickel-iminodiacetic acid--agarose chromatography (WeiShiBoHui, China). After dialysis using binding buffer (10 mM Tris--HCl, pH 8.0, 1 mM EDTA, 0.2 mM dithiothreitol, 20 g/ml bovine serum albumin, 1.2% glycerol) and concentration using 10 or 3-kDa-cutoff centrifugal filter units (Millipore, Billerica, MA, United States), the proteins were analyzed and quantified using 12% SDS-PAGE and Bradford assay, respectively ([@B6]).

Electrophoretic Mobility Shift Assay (EMSA)
-------------------------------------------

Electrophoretic mobility shift assay were carried out as described previously ([@B18]). Briefly, biotin-labeled probe *lmbAp* (5 ng) was incubated with His~6~-LmbU or variants (different concentrations) in the binding reaction mixture contained 10 mM Tris--HCl (pH 8.0), 1 mM EDTA, 0.2 mM dithiothreitol, 20 g/mL bovine serum albumin, 1.2% glycerol, and 50 g/mL poly (dI-C). After incubation at 28°C for 20 min, the samples were separated on 6% non-denaturing polyacrylamide gels in 0.5 × TBE buffer (54 g/L Tris, 1.86 g/L EDTA and 27.5 g/L boric acid, pH 8.0) in ice-water bath at 100 V, and transferred to the positively charged nylon membrane. The biotin-labeled probes were detected by streptavidin- horseradish-peroxidase (HRP) conjugate and BeyoECL Plus (Beyotime Biotechnology, China). Each experiment was at least repeated two times, and the representative images are shown.

xylTE Reporter Assays
---------------------

To analyze the function of LmbU and its variants *in vivo*, we performed *xylTE* reporter assays. DNA fragments covering LmbU expression cassettes (*ermE^∗^p* promoter plus *lmbU* gene or *lmbU* variants) were amplified by PCR using primer pairs E*^∗^*p-lmbU-F/R with pLU-1, pLU-03, and pLU-06 as templates, and using primer pairs E*^∗^*p-lmbU-F/lmbU4-R with pLU-2 and pLU-7 as templates. The amplified fragments were inserted into the *Nhe*I restriction sites of the pATE152 plasmid by using T4 DNA ligase (TAKARA, Japan), resulting in pAU01, pAU02, pAU03, pAU06, and pAU07 plasmids. The obtained plasmids were then introduced into the *lmbU* disruption strain JLUa2 and integrated into the *attB* site of the chromosome to generate reporter strains JAU01, JAU02, JAU03, JAU06, and JAU07. The reporter plasmid pUTE152 was constructed as pATE152 described previously ([@B19]). The region upstream (relative to the translation start codon) of the *lmbU* gene (-329 *--* 1 bp) was amplified using primer pairs pUxyl-1/pUxyl-2, and the *xylTE* gene was amplified by PCR using primer pair pAxyl-3/pAxyl-4. Two fragments were inserted into the *Pvu*II site of the plasmid pSET152 using Super Efficiency Fast Seamless Cloning kits (Do Gene, China). The obtained plasmid was introduced into wild-type strain NRRL 2936 and *lmbU* disruption strain JLUa2, and integrated into the *attB* site of the chromosome to generate reporter strains LNU and LUU.

The analysis of catechol dioxygenase activity was performed as described previously ([@B19]). *Streptomyces* strains were grown in YEME medium at 28°C for 1 day, cells were washed in 20 mM potassium phosphate buffer, and suspended in 1 ml sample buffer (100 mM potassium phosphate, pH 7.5, 20 mM EDTA, 10% acetone). Total proteins were harvested by sonication, and quantified using the Bradford method ([@B6]). 20 μl total proteins were added to 180 μl assay buffer (100 mM potassium phosphate, pH 7.5, 1 mM catechol), and were detected at 375 nm at 1, 2, 3, 4, 5, and 6 min, respectively. The activity was calculated as the rate of change per minute per milligram of protein and converted to milliunits per milligram. Data represent means ± standard deviations of results from three independent experiments. Statistical significance is indicated vs. the results of wild-type LmbU by using *T* test ([@B23]), ns, not significant; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001.

Dimerization Analysis of LmbU
-----------------------------

The purified LmbU protein and variants were dealt with different loading buffers, which contained or did not contain SDS or DTT. The total loading buffer consists of 50 mM Tris--HCl (pH 6.8), 2% SDS (m/v), 0.1% bromophenol blue (m/v), 10% glycerin (m/v), and 100 mM DTT. The samples were analyzed by 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) ([Supplementary Table S2](#SM1){ref-type="supplementary-material"}) and stained with Coomassie brilliant blue R-250. The electrophoresis buffer consists of 3 g/L Tris, 19 g/L glycine and 1 g/L SDS. The molecular weights of LmbU dimer (56 kDa) and LmbU monomer (28 kDa) were standardized by the protein marker (TAKARA, Japan).

Results
=======

Bioinformatics Analysis of the Structure of LmbU
------------------------------------------------

In our previous study, we have characterized LmbU as a DNA-binding protein involved in lincomycin biosynthesis, and identified the target genes and the binding site of LmbU ([@B18]). To further investigate the regulatory mechanism of LmbU, we performed bioinformatics analysis of the structure of LmbU. Secondary structure analysis showed that LmbU protein contains 9 α-helices and 2 β-strands. In addition, 14 protein binding regions, one RNA-binding region and 3 DNA-binding regions were predicted in LmbU ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). Structure modeling demonstrated that two potential DBDs, a putative HTH motif including amino acid (aa) 80--102, and a putative ribbon-helix-helix (RHH) motif including aa 167--206, were predicted in LmbU ([Figure 1](#F1){ref-type="fig"}). However, all the templates used for LmbU modeling are not derived from *Streptomyces*, indicating the regulatory pattern of LmbU may be complex and novel compared to other CSRs.

![Bioinformatics analysis of the structure of LmbU. **(A)** Structure based alignment of LmbU with partial structural homologs from various bacteria. Putative HTH and RHH motifs are indicated by blue and green boxes, respectively. *Tt*Spo0J is derived from *Thermus thermophiles* (GenBank accession no. WP_011173975.1), *Hp*Spo0J is derived from *Helicobacter pylori* (GenBank accession no. ACJ08256.1), ParG is derived from a multidrug resistance plasmid TP228 from *E. coli* (GenBank accession no. ACV89876.1), AmrZ is derived from *Pseudomonas aeruginosa* (GenBank accession no. APJ53923.1), ω repressor is derived from a plasmid Psm19035 from *Streptococcus pyogenes* (GenBank accession no. AAR27202.1), and Arc repressor is derived from *Salmonella* bacteriophage P22 (GenBank accession no. AAM81381.1). **(B)** Structural modeling of HTH motif. **(C)** Structural modeling of RHH motif. The results were generated by using a online software SwissModel (<https://www.swissmodel.expasy.org/interactive>).](fmicb-10-00989-g001){#F1}

In addition, LmbU homologs naturally exist in hundreds of actinomycetes ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}), indicating LmbU homologs might play important roles in metabolism of natural products. Sequence alignment of LmbU with eight selected homologs revealed that the HTH motifs are highly conserved, 11 out of 23 amino acids, especially 10 out of 13 amino acids in the latter helix, are totally identical. In contrast, only 7 out of 40 amino acids in the RHH motif are totally identical ([Supplementary Figure S3](#SM1){ref-type="supplementary-material"}). These data indicated that the HTH motif might be more important for DNA-binding than the RHH motif.

Identification of the DNA-Binding Function of HTH and RHH Motifs
----------------------------------------------------------------

To identify whether the HTH or/and RHH motifs were relative to the DNA-binding of LmbU, two deletion variants were constructed and expressed, one deleted the HTH motif (designed as LmbU~DH~) and the other deleted the RHH motif (designed as LmbU~DR~) ([Supplementary Figure S4A](#SM1){ref-type="supplementary-material"}). Unfortunately, His~6~-LmbU~DH~ failed to express in *E. coli* BL21 (DE3). EMSA analysis revealed that His~6~-LmbU~DR~ had the DNA-binding activity ([Supplementary Figure S4B](#SM1){ref-type="supplementary-material"}), suggesting the RHH motif is not critical for DNA-binding of LmbU. To further verify the DNA-binding activities of RHH and HTH motifs, we expressed and purified the His~6~-LmbU~1--161~ (aa 1--161) and His~6~-LmbU~86--225~ (aa 86_225) variants, which contained the intact HTH motif, and the intact RHH motif, respectively ([Figure 2A](#F2){ref-type="fig"}). EMSA analysis demonstrated that His~6~-LmbU~1--161~ could bind to the *lmbAp* probe, while His~6~-LmbU~86--225~ could not ([Figure 2B](#F2){ref-type="fig"}), which also indicated that the RHH motif is not a critical DBD, and the DBD may exist in LmbU~1--161~. Subsequently, *xylTE* reporter assay was carried out to identify the function of the LmbU variants *in vivo*. The reporter plasmid pATE152, where *xylTE* gene was controlled by *lmbAp* promoter, was introduced into wild-type strain NRRL 2936 and *lmbU* disruption strain JLUa2, resulting in reporter strains LNA and LUA, respectively. The data showed that LmbU activates *lmbAp* promoter ([Supplementary Figure S5](#SM1){ref-type="supplementary-material"}), which is available and coincident with that of *neo^r^* reporter assay ([@B18]). In addition, the enzyme activities of total proteins extracted from the cells cultured for 1 day were observed higher than that from the cells cultured for 2 days ([Supplementary Figure S5](#SM1){ref-type="supplementary-material"}), thus, in the following study, we just detected the enzyme activities at day 1. Reporter plasmids pAUTE1 and pAUTE2 were constructed and introduced into JLUa2 strain, respectively, where the *xylTE* gene was controlled by the *lmbAp* promoter and the *lmbU* mutant genes were controlled by *ermE^∗^p*. The data showed that LmbU~1--161~ rather than LmbU~86--225~ could activate the *lmbAp* promoter ([Figure 2C](#F2){ref-type="fig"}), which is consistent with the results of EMSA, showing that LmbU~1--161~ variant contains a pivotal DBD.

![Functional analysis of LmbU variants LmbU~1--161~ and LmbU~86--225~. **(A)** Sketch map of LmbU protein and LmbU variants showing the location of the HTH (aa 80--102) and RHH motif (aa 167--206). **(B)** EMSA analysis of LmbU and variants with *lmbAp* probe. Biotin-labeled *lmbAp* (263 bp, 5 ng) was incubated with increasing concentrations (0, 3.2, 6.4, and 12.8 μM) of His~6~-LmbU, His~6~-LmbU~1--161~, and His~6~-LmbU~86--225~, respectively. The DNA-protein complexes and the free probes are indicated by arrows. **(C)** *XylTE* reporter assay of LmbU and variants to *lmbAp in vivo*. The reporter plasmids were constructed with *xylTE* reporter gene controlled by *lmbAp* and *lmbU* or *lmbU* variants controlled by *ermE^∗^p*. The reporter plasmids were integrated into the *attB* site of the chromosome of JLUa2 to generate reporter strains. In addition, LUA was used as a negative control, which was derived from JLUa2 harboring *xylTE* reporter gene controlled by *lmbAp*. Data represent means ± standard deviations of results from three independent experiments. Statistical significance is indicated vs. the results of wild-type LmbU by using *T* test ([@B23]), ns, not significant, ^∗∗^*P* \< 0.01.](fmicb-10-00989-g002){#F2}

Verification of the DBD and AID of LmbU
---------------------------------------

To narrow down the region of potential DBD of LmbU, we further truncated LmbU~1--161~ to the LmbU~1--141~ and LmbU~1--131~ variants. However, both His~6~-LmbU~1--141~ and His~6~-LmbU~1--131~ were failed to express in *E. coli* BL21 (DE3). Therefore, semi-quantitative reverse transcription and polymerase chain reaction (sqRT-PCR) and Western blotting were performed to check the RNA levels and the protein levels of LmbU variants, respectively. The data demonstrated that RNA levels of *lmbU~1~*\_*~141~* and *lmbU~1~*\_*~131~* had no differences with that of *lmbU*, but protein levels of them were severely reduced compared to that of LmbU ([Supplementary Figure S6](#SM1){ref-type="supplementary-material"}). Then, we extended LmbU~86--225~ to LmbU~58--225~ ([Figure 3A](#F3){ref-type="fig"}) and performed EMSA. The data revealed that His~6~-LmbU~58--225~ could recover the DNA-binding activity, and the affinity to the target seemed enhanced compared to LmbU. Further EMSA analysis showed that the complex bands were observed when 0.2 μM His~6~-LmbU~58--225~ was added ([Figure 3B](#F3){ref-type="fig"}), but that was observed when 3.2 μM His~6~-LmbU was added, indicating N-terminal of LmbU contains an AID against DNA-binding.

![Functional analysis of LmbU variants LmbU~58--225~ and LmbU~58--161~. **(A)** Sketch map of LmbU protein and LmbU variants. LmbU~58--225~ contains intact HTH and RHH motifs, LmbU~58--225~ only contains intact HTH motif. **(B)** EMSA analysis of LmbU and variants with *lmbAp* probe. Biotin-labeled *lmbAp* (263 bp, 5 ng) was incubated with increasing concentrations of His~6~-LmbU~58--225~ and His~6~-LmbU~58--161~, respectively. The DNA-protein complexes and the free probes are indicated by arrows. **(C)** *XylTE* reporter assay of LmbU and variants to *lmbAp in vivo*. Data represent means ± standard deviations of results from three independent experiments. Statistical significance is indicated vs. the results of wild-type LmbU by using *T* test ([@B23]), ns, not significant; ^∗∗^*P* \< 0.01.](fmicb-10-00989-g003){#F3}

Given that both His~6~-LmbU~1--161~ and His~6~-LmbU~58--225~ have DNA-binding activities, we speculated that the DBD of LmbU was located in the overlapping region of the two variants. Thus, we constructed and expressed the His~6~-LmbU~58--161~ variant ([Figure 3A](#F3){ref-type="fig"}) and performed EMSA. As expected, His~6~-LmbU~58--161~ was found to bind to the *lmbAp* probe as well. In addition, the complex bands were observed when 0.1 μM His~6~-LmbU~58--161~ was added, and 0.2 μM protein could completely impede the migration of the *lmbAp* probe ([Figure 3B](#F3){ref-type="fig"}), indicating that LmbU~58--161~ has a better affinity to the target compared to LmbU and LmbU~58--225~. Thus, we demonstrate that LmbU~58--161~ has a DNA-binding activity, and the HTH motif is located in this region, suggesting the HTH motif is possibly a crucial DBD of LmbU. Furthermore, *xylTE* reporter assays showed that LmbU~58--25~ could activate *lmbAp* promoter, but not like the result of EMSA, the activity of LmbU~58--225~ for *lmbAp* promoter was not enhanced compared to that of LmbU ([Figure 3C](#F3){ref-type="fig"}). While, LmbU~58--161~ could not activate *lmbAp* promoter ([Figure 3C](#F3){ref-type="fig"}), indicating that C-terminal of LmbU performed a certain function to regulate the activity of *lmbAp* promoter *in vivo*.

It has been reported that polar and positively charged amino acids are usually important for DNA-binding of regulators, such as arginine ([@B9]; [@B3]). To further verify whether the HTH motif is responsible for DNA-binding, two arginines in the motif, R101 and R102, were, respectively substituted with either an alanine or a similarly charged lysine, resulting in LmbU~R101A~, LmbU~R102A~, LmbU~R101K~, and LmbU~R102K~. EMSA analysis revealed that His~6~-LmbU~R102A~ and His~6~-LmbU~R102K~ could bind to the *lmbAp* probe ([Figure 4A](#F4){ref-type="fig"}) while His~6~-LmbU~R101A~ and His~6~-LmbU~R101K~ could not ([Figure 4B](#F4){ref-type="fig"}), indicating that the HTH motif is a critical DBD and R101 plays a key role in DNA-binding. These data also demonstrated that the HTH motif, not the RHH motif is the DBD of LmbU.

![Effect of R102 and R101 on the DNA-binding activity of LmbU. **(A)** EMSA analysis of LmbU variants His~6~-LmbU~R102A~ and His~6~-LmbU~R102K~ with *lmbAp* probe. **(B)** EMSA analysis of LmbU variants His~6~-LmbU~R101A~ and His~6~-LmbU~R101K~ with *lmbAp* probe.](fmicb-10-00989-g004){#F4}

Insight Into Regulation of LmbU to *lmbUp*
------------------------------------------

In our previous study, we found that LmbU regulates the *lmbC*, *lmbK* and *lmbU* genes, but does not bind to their promoters ([@B18]). Considering the DNA-binding activities of LmbU~58--225~ and LmbU~58--161~ were enhanced compared to that of LmbU, we performed EMSA using LmbU~58--225~ and LmbU~58--161~ with *lmbCp*, *lmbKp* and *lmbUp* probes, the P~V\ -W~3 probe was used as a positive control. The data showed that both His~6~-LmbU~58--225~ and His~6~-LmbU~58--161~ could not bind to the *lmbCp* and *lmbKp* probes, but seemed to bind to the *lmbUp* probe ([Supplementary Figure S7](#SM1){ref-type="supplementary-material"}). Subsequently, further EMSA with competition analysis were carried out using His~6~-LmbU~58--225~ and LmbU~58--161~ with the *lmbUp* probe. The results showed that both of the two variants can bind to *lmbUp* directly and specifically with a concentration-dependent manner ([Figure 5A](#F5){ref-type="fig"} and [Supplementary Figure S8](#SM1){ref-type="supplementary-material"}). In addition, *xylTE* reporter assay showed that LmbU represses the activity of the *lmbUp* promoter *in vivo* ([Figure 5B](#F5){ref-type="fig"}), indicating that LmbU might regulate the activity of *lmbUp* promoter by binding to *lmbUp* in a different pattern compared to *lmbAp* and *lmbWp*.

![Regulation of LmbU to its own promoter *lmbUp*. **(A)** EMSAs of LmbU 58--161 with *lmbUp* probe. Biotin-labeled *lmbUp* (415 bp, 5 ng) probes were incubated with increasing His6-LmbU 58--161 (0, 6.4, 12.8, and 25.6 μM). EMSAs with 200-fold excess of unlabeled specific DNA or non-specific DNA were added as controls, to confirm specificity of the band shifts. The DNA-protein complexes and the free probes are indicated by arrows. **(B)** *XylTE* reporter analysis of the effect of LmbU to *lmbUp in vivo*. LNU, wild-type strain NRRL 2936 harboring the reporter plasmid pUTE152; LUU, *lmbU* disruption strain JLUa2 harboring the reporter plasmid pUTE152. Data represent means ± standard deviations of results from three independent experiments. Statistical significance is indicated vs. the results of wild-type LmbU by using *T* test ([@B23]), ^∗∗^*P* \< 0.01.](fmicb-10-00989-g005){#F5}

Identification of Dimerization of LmbU
--------------------------------------

Generally, regulatory proteins perform their functions by forming homodimers ([@B3]; [@B15]). To investigate the polymeric form of LmbU, we performed SDS-PAGE by using purified LmbU and variants from *E. coli* BL21 (DE3), which were dealt with different loading buffers (containing DTT/SDS or not). The data showed that LmbU could form a homodimer, which was affected by DTT, but not by SDS ([Figure 6A](#F6){ref-type="fig"}), indicating that the homodimer is likely to be formed by disulfide bond among cysteines. Sequence analysis showed that LmbU contains three cysteines, C12, C63, and C196, the first two of which are included in LmbU~1--161~ and the last one is included in LmbU~113--225~. To figure this out, we firstly carried out SDS-PAGE using LmbU~1--161~ and LmbU~113--225~, respectively, and found that the former could form homodimer, but the latter could not ([Figure 6B](#F6){ref-type="fig"}), suggesting the crucial cysteines for dimerization were located in aa 1--161. Then, the two cysteines C12 and C63 were mutated to glycines, resulting in the LmbU~C12G~, LmbU~C63G~ and LmbU~C12G/C63G~ variants. SDS-PAGE analysis revealed that LmbU~C12G~ and LmbU~C12G/C63G~ could not form homodimer, but LmbU~C63G~ could form homodimer partly ([Figure 6C](#F6){ref-type="fig"}), indicating C12 plays a key role in forming LmbU homodimer, and C63 plays a supporting role.

![Dimerization analysis of LmbU. **(A)** The LmbU protein was dealt with SDS, DTT, or was boiled for 5 min. −, not dealt with; + dealt with. **(B)** Dimerization analysis of LmbU variants LmbU113-225 and LmbU1-161. **(C)** Effect of C12 and C63 on LmbU dimer.](fmicb-10-00989-g006){#F6}

Discussion
==========

In our previous study, we have demonstrated that a global regulator BldA ([@B19]) and a CSR LmbU ([@B18]) are involved in lincomycin biosynthesis. Recently, a TetR-type regulator SLCG_2919 has been proved to negatively regulate lincomycin biosynthesis ([@B51]). However, the regulatory mechanism of lincomycin biosynthesis is still unclear at present.

Importantly, we found that hundreds of LmbU homologs exist in or outside the BGCs of different natural products derived from a variety of actinomycetes ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}), indicating LmbU homologs might play important roles in metabolism and do not only act as CSRs of natural products. Although there are so much LmbU homologs, few studies have been reported. SACE_5599, a homolog of LmbU outside the BGCs of natural products, can regulate not only erythromycin production, but also morphological differentiation in *Saccharopolyspora erythraea* ([@B24]), which has been shown to bind to the promoter regions of *lmbAp*, and *lmbWp* within *S. lincolnensis* as well in our previous study ([@B18]). HmtD, a homolog of LmbU in the BGC of himastatin, positively regulates the biosynthesis of himastatin in *Streptomyces hygroscopicus*, however, the relevant mechanism is still unknown ([@B50]). In addition, structural prediction of LmbU demonstrated that LmbU protein does not include a known domain similar to that of other CSRs, indicating the regulatory pattern of LmbU and its homologs was novel and complex compared to other CSRs. In the present study, we illuminate the functional domains of LmbU, including DBD and AID, and insight into the regulatory pattern of LmbU.

We demonstrated that LmbU consists of three functional domains, including a N-terminal AID (aa 1--57), a central DBD (aa 80--102), and a C-terminal unknown domain (aa 162--225) ([Figure 7](#F7){ref-type="fig"}). To our knowledge, HTH motif is the best known and widely used DBD, although LmbU has been shown to bind to the targets by HTH motif as well, the sequence, and structure of HTH motif within LmbU is unlike the most of the regulators in *Streptomyces* ([@B33]; [@B12]; [@B14]), indicating LmbU and its homologs function in a novel regulatory mechanism.

![A hypothetical model for the functional domains of LmbU.](fmicb-10-00989-g007){#F7}

Furthermore, we found that the N-terminal AID represses the DNA-binding of LmbU, and without this domain, LmbU variants can bind to its own promoter region and inhibit transcription of itself, forming negative feedback regulation ([Figure 5](#F5){ref-type="fig"}). Moreover, we found that LmbU homologs within the BGCs of the known antibiotics all contain the N-terminal AID ([Supplementary Figure S3](#SM1){ref-type="supplementary-material"}), such as HrmB (GenBank Accession No. AEH41782.1) for hormaomycin ([@B17]), HmtD (GenBank accession no. CBZ42138.1) for himastatin ([@B31]), and AcmO (GenBank accession no. ADG27350.1) for actinomycin ([@B22]). Thus, we speculate that whether LmbU and its homologs within the BGCs of antibiotics function in a more complicated manner, by forming different conformations or different variants. These kinds of cases are not common in the known CSRs, but were found in global regulators. For instance, in *Bacillus subtilis*, the C-terminal of GlnR acts as an auto-inhibitory domain (AID) repressing dimer formation and DNA-binding, when interacting with DNA, GlnR changes its conformational and oligomeric state, resulting in a stable complex ([@B10]; [@B49]; [@B38]). In *S. coelicolor*, BldD undergoes degradation of the C-terminal domain, resulting in two forms, which may play roles at vegetative stage or at the late stage of life cycle, respectively ([@B27]). Interestingly, two PmbA (TldE)-TldD family proteins, LmbIH and LmbQ, are found in the lincomycin BGC. As reported, in *E. coli*, TldD and TldE participate in the cleavage of the modified MccB17 precursor peptide to mature antibiotic by forming heterodimer ([@B1]; [@B36]; [@B11]). These studies promote us to speculate that LmbU may undergo accurate post-translational modification by LmbIH and LmbQ in the late growth stage, resulting in functional variant, which binds to its own promoter, and inhibits the biosynthesis of lincomycin. However, further studies are needed to confirm these hypotheses.

In addition, we demonstrated that compared to the functional variant LmbU~58--225~, LmbU~58--161~ can bind to the target DNA *in vitro* with a better affinity, but can not activate transcription of the reporter gene *in vivo*. Considering LmbU~1--161~ without aa 162--225 has a similar DNA-binding affinity to LmbU, thus we thought there is no inhibitory domain within the C-terminal, the better affinity of LmbU~58--161~ might be due to the exposure of the DBD domain. In addition, these data showed that the C-terminal amino acids play important roles as an unknown domain, either in structural stability or in interaction with ligands. However, we also found that LmbU~1--161~ has activity to *lmbAp* promoter both *in vitro* and *in vivo*, indicating the C-terminal domain is not necessary, which appeared to be different from the hypothesis mentioned above. In consideration of the unclear regulatory mechanism of LmbU to the target *lmbCp* and *lmbKp* with no identified binding sites, the function of the C-terminal domain needs to be further illuminated.

Generally, transcriptional regulators bind to the target DNA by forming homodimers. For instance, in *Streptomyces griseus*, a global regulator AdpA either binds to two sites with different lengths in the target DNA (type I or type I'), or binds to a single site in the target DNA with one subunit of the homodimer (type II) ([@B52]); in *S. coelicolor* A3 (2), a γ-butyrolactone receptor CprB interacts with the target DNA through two individual CprB homodimers ([@B3]). Here, we showed that LmbU can form homodimer mainly via C12. And the DNA-binding mode of LmbU need to be further investigated.

In summary, we have demonstrated the functional domains of LmbU, which is a representative of the LmbU family transcriptional regulators. LmbU consists of an N-terminal AID, a central DBD and a C-terminal unknown domain. In addition, LmbU forms homodimer mainly via the C12 *in vitro*. By applying this knowledge, we speculate that the unusual properties of LmbU will be exploited for future applications in the realization of high-yield of lincomycin, and in the functional research of LmbU family proteins.
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